News

PLX3397 is an oral agent that selectively co-inhibits three key targets, allows down-modulation of a number of cell types, as well as inhibits Flt3 mutations that are responsible

The company hopes to generate an additional production capacity of more than 150,000kg per year within a year. The expansion of facility will be executed in two phases,

Rozrolimupab is a fully human recombinant anti-RhD monoclonal antibody (mAb) mixture, produced by a single-batch manufacturing strategy designed to capture the natural diversity of the human antibody response

As per the collaboration, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and thereby help Ono’s structure-based drug

The two bispecific antibodies were developed using the company’s protein conjugation technology, Dock-and-Lock (DNL). The two anti-CD20/CD74 antibodies showed inhibition in the growth of MCL cell lines, as

Veltuzumab, a humanized anti-CD20 antibody was constructed using the same human donor frameworks as epratuzumab. The results demonstrated that two doses of veltuzumab produced an overall objective response

Mydicar is a genetically targeted enzyme replacement therapy designed to restore levels of SERCA2a, that regulates calcium cycling and contractility. The randomized double-blind placebo-controlled Phase 2 Calcium Up-regulation

The siRNA liposome technique is used in biology laboratories to enable in vivo delivery of siRNA and uses microfluidizer (Microfluidics) technology. According to the company, in vivo siRNA-induced

According to Ablynx, this is the first pre-clinical candidate that has emerged from the collaboration. Ablynx is entitled to a milestone payment of EUR1m, under the terms of